Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects.
Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects.
复制标题
卵巢癌的新型非细胞毒性疗法：现状和未来前景。
DOI：
--
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
R. Schilder
中科院分区：
文献类型：
--
作者：
Lainie P Martin;R. Schilder
尽管在过去的十年中，卵巢癌的标准治疗取得了显著的进步，但目前的治疗受到对细胞毒化疗产生耐药性的限制，大多数女性最终死于这种疾病。对卵巢癌生物学的新认识导致了在正常细胞和癌细胞中差异表达的潜在分子靶点的确定，药理学的进步也导致了通过利用这些靶点而开发出不同于传统细胞毒性化疗的新药物。其中许多药物正在进行临床试验评估。本文讨论了在卵巢癌中起重要作用的分子靶点，包括血管生成、酪氨酸激酶、丝裂原激活的蛋白激酶和磷脂酰肌醇样激酶，如哺乳动物的雷帕霉素靶点和蛋白小体。本文综述了针对这些途径的新型非细胞毒性药物，目前正在评估其在卵巢癌治疗中的作用。
Although significant improvements in standard therapy for ovarian carcinoma have been made over the past decade, current treatment is limited by the development of resistance to cytotoxic chemotherapy, and most women ultimately die of the disease. New knowledge of the biology of ovarian cancer has led to the identification of potential molecular targets that are differentially expressed in normal cells versus cancer cells, and advances in pharmacology have led to the development of novel agents that work differently from traditional cytotoxic chemotherapy by exploiting these targets. Many of these agents are being evaluated in clinical trials. This article discusses molecular targets that are important in ovarian carcinoma, including angiogenesis, tyrosine kinases, mitogen-activated protein kinases, and phosphatidylinositol-like kinases such as mammalian target of rapamycin, and the proteosome. This article reviews novel non-cytotoxic agents that target these pathways and are currently being evaluated in ovarian carcinoma treatment.
登录
查看更多内容
影响因子：
20.3
作者：
Barlogie, B;Desikan, R;Tricot, G
通讯作者：
Tricot, G
影响因子：
11.8
作者：
Lenz, HJ
通讯作者：
Lenz, HJ
影响因子：
10.3
作者：
del Carmen, MG;Rizvi, I;Hasan, T
通讯作者：
Hasan, T
影响因子：
158.5
作者：
Singhal, S;Mehta, J;Crowley, J
通讯作者：
Crowley, J
影响因子：
45.3
作者：
Orlowski, RZ;Stinchcombe, TE;Soignet, SL
通讯作者：
Soignet, SL